Global Partners LP(GLP)

Search documents
Top 3 Energy Stocks That May Rocket Higher In October
Benzinga· 2025-10-17 11:12
The most oversold stocks in the energy sector presents an opportunity to buy into undervalued companies.The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro.Here's the latest list of major oversold players in th ...
Top 3 Energy Stocks That May Rocket Higher In October - Mach Natural Resources (NYSE:MNR), Global Partners (NYSE:GLP)
Benzinga· 2025-10-17 11:12
The most oversold stocks in the energy sector presents an opportunity to buy into undervalued companies.The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro.Here's the latest list of major oversold players in th ...
Lilly's oral GLP-1 drug helps reduce blood sugar levels in late-stage trials
Reuters· 2025-10-15 10:51
Eli Lilly said on Wednesday its oral drug, orforglipron, helped reduce blood sugar levels in two late-stage trials. ...
Lilly's oral GLP-1, orforglipron, demonstrated superior glycemic control in two successful Phase 3 trials, reconfirming its potential as a foundational treatment in type 2 diabetes
Prnewswire· 2025-10-15 10:45
Accessibility StatementSkip Navigation In ACHIEVE-2, orforglipron lowered A1C by up to 1.7% compared to 0.8% with dapagliflozin, meeting the primarv endpoint In ACHIEVE-5. orforglipron lowered A1C by an additional 2.1% when taken with insulin glargine, meeting the primarv endpoint INDIANAPOLIS, Oct. 15, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 ACHIEVE-2 and ACHIEVE-5 trials. ACHIEVE-2, the second head-to- head trial in the program, eval ...
Global Partners: A Midstream Underdog Ready For The Next Energy Upcycle
Seeking Alpha· 2025-10-14 10:47
As of 2025, I've got over 10 years of researching companies. In total, throughout my investing life, I estimate that I researched (in depth) well over 1000 companies, from commodities like oil, natural gas, gold and copper to tech like Google or Nokia and many emerging market stocks, which I believe could help me provide useful content for readers. After writing my own blog for about 3 years, I decided to switch to a value investing-focused YouTube channel, where I researched hundreds of different companies ...
Ascletis Selects a Best-In-Class Once-Monthly Subcutaneously Administered GLP-1R/GIPR Dual Peptide Agonist, ASC35, for Clinical Development
Prnewswire· 2025-10-13 00:10
- In head-to-head non-human primate (NHP) studies, average observed half-life of ASC35 was approximately 14 days, 6-fold longer than tirzepatide, which supports once-monthly subcutaneous (SQ) dosing in humans. - In head-to-head NHP studies, drug exposures of ASC35 intravenous (I.V.) and SQ administration were approximately 80% and 70% greater than tirzepatide I.V. and SQ administration, respectively. - ASC35 was approximately 4-fold more potent than tirzepatide for both GLP-1Â receptor (GLP-1R) and GIPÂ rec ...
Fractyl Health: Best-Case Results; Financing Dilutes But Removes Overhang
Seeking Alpha· 2025-10-01 09:14
Core Insights - The article discusses the investment potential of GUTS, highlighting a beneficial long position in its shares [1]. Group 1 - The analyst expresses a personal opinion on GUTS, indicating no external compensation or business relationships influencing the analysis [1]. - The article emphasizes that past performance does not guarantee future results, suggesting a cautious approach to investment decisions [2].
Metsera Reports Positive Phase 2b Results for First- and Best-in-Class Ultra-long Acting GLP-1 RA Candidate MET-097i, Enabling Rapid Transition into Phase 3
Globenewswire· 2025-09-29 20:01
Core Insights - Metsera, Inc. announced positive topline data from two Phase 2b trials, VESPER-1 and VESPER-3, for its drug MET-097i, showing a placebo-subtracted mean weight loss of up to 14.1% after 28 weeks with no plateau observed [1][3][7] - The drug demonstrated potentially best-in-class tolerability, with minimal diarrhea signals and low rates of nausea (13%) and vomiting (11%) [1][5][6] - High retention rates were noted in both trials, with only 2.9% discontinuation in VESPER-1, supporting the drug's advancement to Phase 3 trials expected to start in late 2025 [2][7] Trial Details - VESPER-1 involved 239 participants with doses ranging from 0.4 mg to 1.2 mg administered weekly over 28 weeks, while VESPER-3 included 268 subjects evaluating multiple monthly doses [2][3] - In VESPER-1, the highest dose of 1.2 mg resulted in a mean weight loss of 14.1%, with individual responses reaching up to 26.5% [3][4] - The ongoing VESPER-3 trial is designed to assess the efficacy and tolerability of MET-097i with a pre-specified interim analysis after 12 weeks [2][8] Efficacy and Tolerability - The drug's efficacy was dose-dependent, with significant weight loss observed at higher doses [3][4] - Tolerability results indicated a placebo-like frequency of gastrointestinal adverse events, with nausea and vomiting risk differences from placebo being 13% and 11%, respectively [5][6] - The tolerability profile of MET-097i at higher doses without titration was comparable to existing agents that require prolonged titration [5][6] Future Development - Metsera plans to initiate a global Phase 3 program in late 2025 based on the positive topline data [7] - Additional Phase 2b trials are ongoing to explore the long-term maintenance profile of MET-097i and its effects in populations with type 2 diabetes [7][8] - MET-097i is positioned as the foundational incretin backbone for multiple clinical programs, indicating a robust pipeline for Metsera [7][9] Technology and Platform - MET-097i is a fully biased, ultra-long acting GLP-1 receptor agonist designed for monthly dosing, showcasing class-leading potency and durability [9][10] - The HALO™ peptide stabilization and lipidation platform enhances the drug's half-life, potentially improving tolerability and scalability [10] Company Overview - Metsera, Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation medicines for obesity and metabolic diseases [11] - The company aims to address multiple therapeutic targets with a broad portfolio of therapies, including oral and injectable options [11]
Autonomix Medical, Inc. Initiates Good Laboratory Practice (GLP) Study for Sensing and RF Ablation System
Globenewswire· 2025-09-29 13:15
Core Viewpoint - Autonomix Medical, Inc. has initiated a Good Laboratory Practice (GLP) preclinical study for its Sensing and RF Ablation System aimed at treating pancreatic cancer pain, marking a significant step towards regulatory approval and potential clinical trials in the U.S. by 2026 [1][2][3] Company Overview - Autonomix is focused on advancing innovative medical technologies for diagnosing and treating diseases related to the nervous system, utilizing a first-in-class platform technology that includes a catheter-based microchip sensing array [6][7] - The company's technology aims to provide transvascular diagnosis and treatment of peripheral nervous system diseases, with initial development targeting pain management in pancreatic cancer [7] Regulatory Pathway - The GLP study is essential for ensuring the reliability and integrity of Autonomix's devices, which is a prerequisite for submitting data to the FDA for Investigational Device Exemption (IDE) clinical trials [2] - The company is on track to file its IDE application, with plans to commence clinical studies in the following year if approved [3] Technological Potential - Autonomix's technology has the potential to address multiple high-need therapeutic areas, including cardiology, resistant hypertension, interventional pain management, and gastrointestinal disorders [4][6] - The platform is designed to tackle a wide spectrum of diseases, indicating a broad market opportunity for the company [7]
Are These GLP-1 Trial Results About to Send Eli Lilly's Stock Soaring?
The Motley Fool· 2025-09-28 14:15
Core Insights - Eli Lilly has shown strong performance in the GLP-1 market, with significant commercial success from its products, particularly tirzepatide [1][10] - The company is on the verge of launching an oral GLP-1 medication, orforglipron, which has demonstrated superior efficacy in clinical trials compared to existing treatments [7][8] - Financial results indicate robust growth, with a 38% year-over-year revenue increase in Q2, reaching $15.6 billion, and a 61% rise in adjusted net earnings per share to $6.31 [10] Group 1: Product Development - Eli Lilly's tirzepatide, marketed as Mounjaro and Zepbound, is generating billions in sales but is administered via injection, which has drawbacks compared to oral medications [3][4] - The company is developing orforglipron, which has shown a 1.9% average blood-sugar reduction and 8.2% weight loss in trials, outperforming Novo Nordisk's Rybelsus [7][8] - If orforglipron receives regulatory approval by year-end, it could significantly boost Eli Lilly's stock value [8][9] Group 2: Financial Performance - Eli Lilly's revenue and earnings growth outpace industry averages, with a forward P/E ratio of 24.7 compared to the healthcare industry's 16.5 [10][11] - Analysts project orforglipron could generate $12.7 billion in revenue by 2030, while tirzepatide is expected to reach nearly $62 billion in revenue by the same year [12][13] - The company has additional products in the pipeline, such as Kisunla for Alzheimer's and Ebglyss for eczema, which could also contribute to future growth [14] Group 3: Market Outlook - Eli Lilly's strong clinical data and market position suggest continued growth in the GLP-1 sector, with expectations for market-beating returns over the next five years [15]